New & Notable
‘Discredited’ CDC panel weakens endorsement for newborns’ hepatitis B shot
After initially delaying a vote, ACIP backed a softer stance that dissenting members warned would cause harm to children in the future.
— BioPharma Dive
Eli Lilly lowers Zepbound costs amid rising calls for affordability
Lilly cuts prices for its weight loss drug Zepbound as the World Health Organization issues its first global GLP-1 obesity guidelines, urging expanded access and affordability.
UK agrees to boost drug prices to dodge US pharma tariffs
A deal announced Monday will see the U.K. temporarily sidestep levies on Britain-originated drugs by loosening rules that restrain prices for new medicines.
— BioPharma Dive
WHO releases its first-ever GLP-1 weight-loss drug guidelines
GLP-1 drugs approved for weight loss can be combined with behavioral therapy as part of a long-term strategy in adults, the WHO says in new guidance.
Healthcare Strategies: A Podcast
-
A podcast for healthcare professionals seeking solutions to today's and tomorrow's top challenges. Hosted by the editors of Xtelligent Healthcare Media, this podcast series focuses on real-world use cases that are leading to tangible improvements in care quality, outcomes, and cost.
Guests from leading provider, payer, government, and other organizations share their approaches to transforming healthcare in a meaningful and lasting way.
View All Episodes
Latest News
-
FDA expands the National Priority Voucher program to oral GLP-1s
The FDA's second wave of National Priority Voucher recipients includes Novo Nordisk and Eli Lilly's oral GLP-1s, expanding the list to 15 products.
-
Lilly advances amylin obesity drug eloralintide to phase 3 trials
Eli Lilly is set to begin late-stage clinical trials of its investigational amylin obesity drug next month, after encouraging phase 2 study results.
-
Top 10 metro areas for manufacturing biologics in 2026
Raleigh ranks as the top U.S. metro for biologics manufacturing investment in 2026, amid skilled labor shortages and shifting federal policies, a new report finds.
-
Innovent, Lilly's mazdutide outdoes Novo's semaglutide in phase 3 trial
Innovent Biologics and Eli Lilly's dual GLP-1/glucagon agonist, mazdutide, beats Novo Nordisk's semaglutide in a phase 3 trial of adults with diabetes and obesity.
-
Report: Bipartisan support for patent reform to lower drug prices
Four in five Americans support changing patent laws to lower drug costs, favoring patent reform over government price controls by 15 points, says a new I-MAK report.
-
Report: Compounded GLP-1 drugs pose safety, quality risks
Compounded GLP-1 drugs pose safety and quality risks, a recent report says, adding to the growing calls for tougher regulatory enforcement.
Features
-
Blurring the line between GLP-1 compounders, counterfeiters
Weak regulatory oversight has allowed 503A compounding facilities to abuse customization rules, blurring the line between GLP-1 compounders and unregulated drug manufacturers.
-
Expanding clinical trial access through technology, support
Systemic barriers continue to restrict clinical trial access, but when deployed correctly, technology can provide patient–provider support and close interoperability gaps.
-
Will the FDA's green list end illegal GLP-1 compounding?
The FDA recently created a green list to regulate imported GLP-1 drug ingredients, yet experts say that weak enforcement could allow illegal compounding operations to continue.
-
Using AI to identify, expose online drug counterfeiters
Pharmaceutical companies are leveraging AI's advanced detection and enforcement tools to combat the online counterfeit drug market, protecting brand integrity and consumer safety.